Long time clinical outcomes of limus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary artery intervention: A meta-analysis of randomized controlled clinical trials

Abstract

Background: The meta-analysis was aimed to compare the long time (> 2 year) clinical outcomes of limus-based stents (LBS) and paclitaxel-eluting stents (PES). LBS and PES are two kinds of most common coronary artery stents in clinics. Methods: Electronic data bases of PubMed, Cochrane, and EMBASE were searched. We included randomized controlled clinical trials (RCT) comparing LBS and PES with long time clinical outcomes. Methodological quality of eligible trials was assessed using "risk of bias" tool. The efficacy endpoints included target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST), and the safety endpoints included all cause death, cardiac death, and myocardial infarction (MI). Odds ratios (OR) and OR = 0.59, TVR: OR = 0.63, ST: OR = 0.55,) and a lower rate of MI (OR = 0.67, . Subgroup analysis showed that both everolimus-eluting stents and sirolimus--eluting stents had better clinical outcomes compared with PES. The comparisons of 3, 4 and 5 year follow-up results revealed that the clinical outcomes of PES were non-inferior to those of LBS but LBS was associated with reduced risk of MI and ST at 3 years. Conclusions: LBS is associated with better clinical outcomes at 2 years. Both LBS and PESshowed similar efficacy and safety at long time period. (Cardiol J 2014; 21, 3: 211-219)

Development and characterization of an ex vivo arterial long-term proliferation model for restenosis research

“…Within the DES group, no significant difference in the proliferation area was found, however there is a trend separating "limus" eluting stents (Xience: everolimus, Resolute Integrity: zotarolimus) and paclitaxel eluting stents (PES). These findings are congruent with most clinical studies describing higher ISR rates with PES (Schomig et al, 2007;Mehilli et al, 2010;Otake et al, 2010;Gao et al, 2014). Therefore, even with a very small number of tested stents this model was able to reflect the clinically well-known differences between BMS and DES and also between "limus" eluting stents and PES.…”

Safety and efficacy profile of bioresorbable‐polylactide‐polymer‐biolimus‐A9‐eluting stents versus durable‐polymer‐everolimus‐ and zotarolimus‐eluting stents in patients with acute coronary syndrome

“…The comparison of different DES is further complicated by various stent variants used . As such, delayed strut endothelialization as a trigger of ST depends on the polymer, strut structure and thickness and drug load .…”

Methyltransferase‐like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formation

“…It is well known that excessive proliferation of vascular smooth muscle cells (VSMCs) is the major cause of neointima formation. Paclitaxel‐eluting stents and limus‐eluting stents are the two common types of stents coated with anti‐proliferative drugs, which significantly improve the long‐term outcomes of patients after stenting 2 . However, the challenge of developing more effective drugs remains formidable.…”

“…Paclitaxel‐eluting stents and limus‐eluting stents are the two common types of stents coated with anti‐proliferative drugs, which significantly improve the long‐term outcomes of patients after stenting. 2 However, the challenge of developing more effective drugs remains formidable. The proliferation of VSMCs is regulated by a variety of molecular mechanisms, and our recently published results showed that autophagy is involved in the growth of VSMCs.…”